OKLAHOMA DEPARTMENT OF CORRECTIONS Suspected Adverse Drug Reaction (ADR) Reporting Form



INSTRUCTIONS: Please PRINT all requested information. Privileged and confidential: All information provided on this form, including any appended materials, is furnished as a report, is privileged and confidential, and is protected by 63 O.S. § 1-1709. This report is to be used solely in the course of internal control for the purposes of reducing morbidity and mortality and improving the quality of inmate care. **Monitor and treat the inmate and report the suspected adverse drug reaction to the medical provider immediately upon discovery. Document the suspected adverse drug reaction in the inmate's medical record if confirmed by the medical provider.**

confirmed by the medi	ical provider.				
Facility: Date/Time of ADR:					
Location of Occurrence: Drug(s) Involved:					
		ODOC #:			
Provider Notified: Yes YNo		Facility CHSA Notified: YYes YNo			
Inmate Notified: Υ Yes Υ No		Pharmacy Notified: Υ Yes Υ No			
Suspected Drug Discontinued: $\Upsilon\text{Yes}\Upsilon\text{No}$		Medical Provider Confirmed ADR Charted: Υ Yes Υ No			
Definition					
An Adverse Drug Read unexpected in doses r	ction (ADR) is defined as a d ecognized in accepted med	letrimental response t ical practice.	o a medication that is unde	esired, unintended, and	
Brief Description of Adverse Drug Reaction:					
Category of ADR					
Fill in Error Category					
 A - Mild ADR: A reaction that is self-limiting and requires no treatment B - Moderate ADR: A reaction that requires treatment and possible hospitalization C - Severe ADR: A reaction that (1) is life-threatening or contributes to the death of an inmate; (2) is permanently disabling; (3) requires intensive medical care; or (4) takes longer than 15 days for recovery to occur 					
Type of Adverse Drug Re	action: (Check all that apply)				
Allergic Y Anaphylaxis Y Fever Y Angioedema Y Urticaria Cardiovascular Y Angina Y Hypertension Y Hypotension Y Tachycardia Y Bradycardia Y Syncope Y Dysrhythmias Y QTc prolongation Y Asystole	ENT Y Hearing loss Y Tinnitus Y Visual disturbance Y Swallowing difficulty Gastrointestinal Y Diarrhea Y Constipation Y Nausea Y Vomiting Y Ulceration/bleeding Y Gastritis Hepatic/Renal Y Elevated liver enzymes Y PT/INR (↑ or ↓) Y BUN/creatinine	Metabolic Balance Y Hypokalemia Y Hyperkalemia Y Hyperglycemia Y Hyperglycemia Neurologic Y Headache Y Seizures Y Vertigo Y Somnolence Y Dyskinesia Y EPS Y Rigors/chills	Respiratory Y Wheezing Y Respirations (↑ or ↓) Y Cough Y Bronchospasm Y Respiratory distress Psychiatric Y Depression Y Confusion Y Hallucinations Y Psychosis Y Agitation Y Combative	Skin Y Pruritus Y Rash edema phlebitis Y Flushing Y Red man syndrome Y Sweating Hematologic Y Bleeding Y Thrombocytopenia Y Leukopenia Y Thrombosis Other (describe)	
Review and Signature of facility CHSA:			Date:		
Please <u>FAX</u> completed report to the chief Medical Officer at <u>405/425-2911</u> within 72 hours of discovery. <u>DO NOT PLACE IN MEDICAL RECORD!</u>					
Office of Medical Services Follow-up: Υ Report forwarded to FDA Υ P&T Committee Υ PI Council					
Drug Reaction Relationship: Y Certain Y Probable Y Possible Y Unlikely					